Antimicrobial compositions

Abstract

The present invention relates to an antimicrobial composition. The present invention provides an antimicrobial composition comprising certain amounts of at least one bisphenol and a monohydric non-phenolic alcohol. The antimicrobial composition provides synergistic antimicrobial benefits, particularly synergistic antiviral benefits.

Description

Field of the Invention

[0001] The present invention relates to antimicrobial compositions. In particular, the present invention relates to antiviral compositions. Background Art

[0002] People take great care of the external surfaces of their bodies, as well as those of their pets, to maintain good overall health. These surfaces include their skin, oral cavity, and scalp. Specific skin-related issues that people are concerned about include healthy and infection-free skin, good complexion, and adequate moisturization. The oral cavity is another external surface that people actively pay attention to maintaining. People generally prefer thick, long hair with little hair loss and an infection-free scalp.

[0003] Many, if not all, problems associated with the skin, oral cavity or scalp are associated with microorganisms such as, for example, bacteria, fungi and viruses. For example, some bacteria such as Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) are commonly found on human skin. Although these bacteria are often present on the skin, they are not pathogenic in themselves. However, when they enter the human body through actions such as ingestion, these bacteria tend to become pathogenic. Most of the problems of the oral cavity (including gums and teeth), such as, for example, caries, tartar, gingivitis, dental caries, bad breath (also known as halitosis) and dental plaque, are associated with the presence of bacteria in the oral cavity. Dandruff is also a frequently occurring scalp problem, also implying a scalp infected by fungal microorganisms.

[0004] In addition, people are also exposed to viruses. Viruses generally have two types: non-enveloped, such as rotavirus and adenovirus, or enveloped, such as hepatitis B virus and respiratory syncytial virus. In enveloped viruses, there is an external lipid membrane, which is not present in non-enveloped viruses. Due to this difference, it is relatively easy to obtain antiviral activity against enveloped viruses, because it is relatively easy to rupture the external lipid membrane when applying antimicrobial actives. However, in order to obtain antiviral activity against non-enveloped viruses, antimicrobial actives need to act on proteins and nucleic acids contained in the virus. Therefore, obtaining antiviral activity against non-enveloped viruses remains a challenge. Reducing even 1log of viral titer in the case of non-enveloped viruses is considered to be a significant benefit.

[0005] People often encounter the common cold, which is caused by viruses such as adenovirus. Further, norovirus is a common cause of gastroenteritis in humans. Norovirus is considered to have similarities with feline calicivirus (FCV). Due to this similarity, FCV is widely used in research. For example, studies have been conducted in which the effectiveness of hand washing was evaluated based on FCV removal.

[0006] Because microorganisms such as bacteria, viruses and fungi sometimes cause undesirable effects, people often tend to get rid of or minimize exposure to microorganisms. For this reason, they take care of their external surfaces by keeping them free of microorganisms, including skin such as, for example, the skin of their hands, oral cavity and scalp. One way to address infection is to treat the infection with an antimicrobial active after the infection has come on. However, another approach is to leave very small amounts of antimicrobial actives on these surfaces, so as to kill or inactivate any invasive microorganisms, thereby minimizing the spread of infection.

[0007] Several references to certain actives and the antimicrobial benefits obtained therefrom are found in the prior art.

[0008] WO11038797 (Beiersdorf AG, 2009) discloses the use of magnolol or honokiol as antibacterial, antifungal, antiparasitic or antiviral active ingredient, wherein in each case only one of the two active ingredients is used.

[0009] US2009156551 (DSM, 2009) discloses compositions comprising magnolol and honokiol, wherein the molar ratio of magnolol to honokiol is less than 0.6, and the use of these compositions as medicaments, in particular as medicaments for the treatment, adjuvant treatment or prevention of inflammatory disorders.

[0010] WO0182922 (Procter and Gamble, 2001) discloses an oral composition comprising an effective amount of a polyphenolic herbal extract selected from magnolol, honokiol, tetrahydromagnokiol, tetrahydrohonokiol and mixtures thereof; an effective amount of a buffer; about 40% to about 99% of one or more aqueous carriers; wherein the oral composition has a total water content of about 5% to about 70%.

[0011] CN101002798 (Guo Zijie) discloses a medicine in the form of a spray for preventing and treating beriberi and its complications, wherein the composition comprises gamba, 0.01 to 9% magnolol, menthol, borax, 3 to 45% ethanol, urea and purified water. The composition relates to a cold sterilizing foot spray.

[0012] Despite the efforts made to date, new technologies for delivering antimicrobial benefits are continually sought.Thus, antimicrobial compositions and actives that deliver antimicrobial benefits remain a subject of interest.

[0013]

[0006] Therefore, there is a need to provide antimicrobial compositions comprising one or more actives that deliver antimicrobial benefits.

[0014] An object of the present invention is to provide an antimicrobial composition for use against common pathogenic viruses.

[0015] Another object of the present invention is to provide a synergistic antimicrobial benefit, in particular a synergistic antiviral benefit, within a relatively short contact time.

[0016] Another object of the present invention is to provide an antiviral composition. The inventors surprisingly found that the combination of at least one compound selected from bisphenols and a monohydric non-phenolic alcohol provides a synergistic antimicrobial benefit. In particular, it provides a synergistic antiviral benefit. Moreover, it provides such benefits within a relatively short contact time, such as 15 seconds. It was also found that such antimicrobial benefits are obtained with a relatively short contact time against Gram-positive and Gram-negative microorganisms. Summary of the invention

[0017] In a first aspect, the present invention relates to an antimicrobial composition comprising:

[0018] a. 0.001 to 10% by weight of at least one bisphenol; and

[0019] b. 50 to 80% by weight of monohydric non-phenolic alcohol.

[0020] In a second aspect, the present invention relates to a method of cleaning or disinfecting a surface comprising the step of applying to the surface a composition of the first aspect.

[0021] In a third aspect, the invention relates to the use of a composition of the first aspect for antimicrobial benefit.

[0022] In a fourth aspect, the invention relates to the use of the composition of the first aspect for improved hand hygiene. DETAILED DESCRIPTION

[0023] Any feature of one aspect of the present invention can be used for any other aspect of the present invention. The word "comprising" is intended to mean "including", but not necessarily "consisting of" or "composed of". In other words, the listed steps or options do not need to be exhaustive. Unless in the operating and comparative examples, or when otherwise explicitly stated, all numbers in this specification indicating the amount of material or reaction conditions, the physical properties of the material and / or the use should be understood to be modified by the word "about". Numerical ranges expressed in the "x to y" format should be understood to include x and y. When multiple preferred ranges are described in the "x to y" format for a particular feature, it should be understood that all ranges combining different endpoints are also contemplated.

[0024] In a first aspect, the present invention relates to an antimicrobial composition comprising:

[0025] a. 0.001 to 10% by weight of at least one bisphenol; and

[0026] b. 50 to 80% by weight of monohydric non-phenolic alcohol.

[0027] Preferably, the antimicrobial composition according to the present invention can be an antiviral composition, an antibacterial composition, an antifungal composition. More preferably, the antimicrobial composition according to the present invention can be an antiviral composition or an antibacterial composition. Most preferably, the antimicrobial composition according to the present invention is an antiviral composition.

[0028] Bisphenol

[0029] The composition according to the invention (the composition) comprises at least one bisphenol.

[0030] Examples of bisphenols suitable for use in the present invention include 2,4′-bisphenol (IUPAC name: 2,4′-dihydroxybiphenyl), 2,2′-bisphenol (2,2′-dihydroxybiphenyl), 3,3′-bisphenol (3,3′-dihydroxybiphenyl), 4,4′-bisphenol (4,4′-dihydroxybiphenyl), and mixtures thereof.

[0031] If the bisphenol contained in the composition is 2,2'-bisphenol, it is preferred that it is used in unsubstituted form.

[0032] Preferably, the bisphenol is diallyl bisphenol. This means that the bisphenol contains diallyl substitution. The diallyl substitution can be present at any of the positions on the bisphenol structure. Preferred diallyl bisphenols are (5-3'-diallyl) bisphenol or (5-5'-diallyl) bisphenol. The most preferred diallyl bisphenol is (5-3'-diallyl) bisphenol.

[0033] Preferably, the composition comprises 0.001 to 10%, preferably 0.005 to 8%, more preferably 0.01 to 6%, even more preferably 0.05 to 5%, further more preferably 0.1 to 4%, still more preferably 0.5 to 3%, and still more preferably 1 to 1.5% by weight of bisphenol.

[0034] Monovalent non-phenolic alcohol

[0035] The composition also comprises non-phenolic alcohols. Preferably, alcohols having straight or branched carbon atoms preferably containing 1 to 16, more preferably 2 to 10, even more preferably 3 to 8 carbon atoms are suitable for use in the composition. Illustrative examples of alcohols that can be used in the composition include methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, n-pentanol, n-hexanol and mixtures thereof. Preferably, the alcohol is selected from ethanol, isopropanol and mixtures thereof.

[0036] Preferably, the composition comprises 50 to 80%, more preferably 55 to 75%, even more preferably 58 to 72%, still more preferably 60 to 70%, still more preferably 61 to 68% and most preferably 62 to 65% by weight of non-phenolic monoalcohol.

[0037] Desirably, the amount of monohydric non-phenolic alcohol that may be present in the composition does not exceed 80% by weight of the composition. When monohydric non-phenolic alcohols such as ethanol are used in amounts greater than 80%, they tend to evaporate more quickly and are considered less effective on the substrate to which they are applied. Additionally, such high amounts of alcohol are also believed to be associated with skin dryness and irritation.

[0038] Surfactants

[0039] Preferably, the composition further comprises a surfactant that provides a cleaning benefit. Preferably, the surfactant is selected from anionic, nonionic, cationic, amphoteric surfactants and mixtures thereof. More preferably, the surfactant is selected from cationic surfactants, nonionic surfactants and mixtures thereof. Most preferably, the surfactant is selected from nonionic surfactants.

[0040] Preferred anionic surfactants include soaps, alkyl ether sulfates and sulfonates, alkyl sulfates and sulfonates, alkyl benzene sulfonates, alkyl and dialkyl sulfosuccinates, C8-C 20 Acyl isethionate, acyl glutamate, C8-C 20 Alkyl ether phosphates and mixtures thereof.

[0041] Preferred nonionic surfactants are those having: C 2-100 moles of ethylene oxide or propylene oxide condensed with 2 to 100 moles of ethylene oxide or propylene oxide per mole of hydrophobe. 10 -C 20 A fatty alcohol or an acid hydrophobe, condensed with 2 to 20 mol of alkylene oxides, C2-C 10 Alkylphenols; Mono- and di-fatty acid esters of ethylene glycol; Monoglycerides of fatty acids; Sorbitan, mono- and di-C8-C 20 Fatty acids; block copolymers (ethylene oxide / propylene oxide); polyoxyethylene sorbitan, and mixtures thereof. Alkyl polyglycosides and carbohydrate fatty amides (eg, methyl glucamide) are also suitable nonionic surfactants.

[0042] Preferred cationic surfactants include cetyl trimethyl ammonium bromide, benzalkonium halides (which are also known as alkyl dimethyl benzyl ammonium halides). A preferred cationic surfactant that may be used in the composition is benzalkonium chloride, also known as alkyl dimethyl benzyl ammonium chloride.

[0043] Preferred amphoteric surfactants include amides, betaines and amine oxide types. Particular amphoteric surfactants include coconut diethanolamide and coconut monoethanolamide, cocamidopropyl betaine and cocamidopropyl amine oxide. A preferred amphoteric surfactant that can be used as a surfactant in the composition is cocamidopropyl betaine.

[0044] When incorporated into the composition, the surfactant may be present in an amount of from 1 to 80%, preferably from 3 to 60%, more preferably from 5 to 40%, even more preferably from 7 to 30%, further more preferably from 9 to 15% by weight of the composition.

[0045] Preferably, the composition further comprises a cosmetically acceptable base. The cosmetically acceptable base is preferably in the form of a cream, lotion, gel or emulsion.

[0046] The composition can be prepared using different cosmetically acceptable emulsified or non-emulsified bases. A highly suitable base is a cream. Vanishing cream is particularly preferred. Vanishing cream bases generally contain a mixture of fatty acids and soap. Vanishing cream bases impart a highly desirable matte feel to the skin. In vanishing cream bases, C 12 To C 20 Fatty acids are particularly preferred, and C 14 To C 18 Fatty acids. Most preferably, the fatty acids are stearic acid or palmitic acid or mixtures thereof. The fatty acids are typically hystric acid, which is essentially a mixture of (typically 90 to 95% by weight) 45% stearic acid and 55% palmitic acid. Therefore, it is within the scope of the present invention to include hystric acid and its soap to prepare the composition of the present invention. The fatty acids in the composition are preferably present in an amount of 5 to 20%, more preferably 6 to 19% and even more preferably 7 to 17% by weight of the composition. The soap in the vanishing cream base includes an alkali metal salt of a fatty acid, such as a sodium salt or a potassium salt, most preferably potassium stearate. The soap in the vanishing cream base is typically present in an amount of 0.1 to 10% by weight of the composition, more preferably 0.1 to 3% by weight. Typically, the vanishing cream base topical composition is prepared by taking the desired amount of total fatty matter and mixing it with the desired amount of potassium hydroxide. Soap is typically formed in situ during the mixing process.

[0047] A particularly suitable cosmetically acceptable matrix is ​​one comprising a water-in-oil emulsion comprising silicone oil as continuous phase. The water-in-oil emulsion preferably comprises a crosslinked silicone elastomer blend.

[0048] The inclusion of silicone elastomer blends in water-in-oil emulsions can be used as cosmetically acceptable bases for preparing the compositions of the present invention. Although silicone fluids can be used, cross-linked silicone elastomers are particularly preferred. Compared with silicone fluid polymers, the physical properties of elastomers generally depend on the number of crosslinks, rather than the molecular weight. The ability of silicone elastomers to swell makes them ideal thickeners for oil phases. When applied to the skin or hair, elastomers have a very smooth and soft feel. They can also be used as delivery agents for fragrances, vitamins and other additives in cosmetic compositions. Suitable silicone elastomer blends or gels that are commercially available and suitable for inclusion in the compositions of the present invention and found to provide enhanced stability are: Dow EL-8051 IN Silicone Organic Elastomer Blend [INCI Name: Isodecyl Neopentanoate (and) Dimethicone / Bis-Isobutyl PPG-20 Crosspolymer]; EL-8050 [INCI Name: Isododecane (and) Dimethicone / Bis-Isobutyl PPG 20 Crosspolymer]; DC9040, DC9041, DC9045 (Dimethicone Crosspolymer); DC9506, DC9509 (Dimethicone Vinyl Dimethicone Crosspolymer); and Shin-Etsu KSG-15, KSG-16, KSG-17 (Dimethicone Vinyl Dimethicone Crosspolymer). It is further preferred that the composition comprises 5 to 50% by weight of the silicone elastomer.

[0049] Water and / or polyols may also be used as cosmetically acceptable bases. Polyols typically include ethylene glycol or propylene glycol, or homologs such as diethylene glycol may be used.

[0050] Preferably, the cosmetically acceptable base is present in preferably 10 to 99.9%, more preferably 50 to 99%, even more preferably 60 to 85% and further more preferably 65 to 80% by weight of the composition.

[0051] Preferably, the composition further comprises a skin lightening agent. Examples of skin lightening agents that can be used in the composition include 12-hydroxystearic acid, aloe extract, ammonium lactate, arbutin, azelaic acid, kojic acid, butylated hydroxyanisole, butylated hydroxytoluene, citric acid esters, 3-diphenylpropane derivatives, 2,5-dihydroxybenzoic acid and its derivatives, ellagic acid, fennel extract, pyranosyl-1-ascorbic acid, gluconic acid, glycolic acid, green tea extract, hydroquinone, 4-hydroxyanisole and its derivatives, 4-hydroxybenzoic acid derivatives, hydroxyoctanoic acid, lemon extract, linoleic acid, magnesium ascorbyl phosphate, mulberry root extract, 2,4-resorcinol derivatives, 3,5-resorcinol derivatives, salicylic acid, vitamins (such as vitamin B6, vitamin B12, vitamin C, vitamin A), dicarboxylic acids, resorcinol derivatives, hydroxycarboxylic acids (such as lactic acid) and their salts (such as sodium lactate), and mixtures thereof.

[0052] Preferably, the composition further comprises one or more sunscreens. Any sunscreen that can be suitably used with the matrix may be added. Both UVA and UVB sunscreens may preferably be added.

[0053] The composition of the present invention may preferably comprise a UV-A sunscreen which is dibenzoylmethane or a derivative thereof. Preferred dibenzoylmethane derivatives are selected from 4-tert-butyl-4'-methoxydibenzoylmethane, 2-methyldibenzoylmethane, 4-methyl-dibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5-dimethyldibenzoylmethane, 4,4'-diisopropyl-dibenzoylmethane, 2-methyl-5-isopropyl-4'-methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'-methoxy-dibenzoylmethane, 2,4-dimethyl-4'-methoxydibenzoylmethane or 2,6-dimethyl-4-tert-butyl-4'-methoxy-dibenzoylmethane. The most preferred dibenzoylmethane derivative is 4-tert-butyl-4'-methoxydibenzoylmethane. The composition of the present invention preferably comprises 0.1 to 10 wt%, more preferably 0.2 to 5 wt%, still more preferably 0.4 to 3 wt% of dibenzoylmethane or its derivatives based on the total weight of the composition, and including all ranges subsumed therein.

[0054] The composition may also preferably comprise a UV-B organic sunscreen selected from the class of cinnamic acid, salicylic acid, diphenyl acrylic acid and derivatives thereof. An illustrative, non-limiting example of a commercially available UV-B sunscreen useful for inclusion in the composition of the present invention is octisalate. TM Homosalate TM 、NeoHelipan TM Octocrylene TM , Oxybenzone TMor Parsol MCX TM The most preferred UV-B sunscreen is 2-ethyl-hexyl-4-methoxycinnamate, which is available as Parsol MCX TM Commercially available. UV-B organic sunscreens are preferably included in the composition at 0.1 to 10 wt %, more preferably 0.1 to 7 wt % of the composition. It has been observed that the presence of organic UV-B sunscreens such as 2-ethyl-hexyl-4-methoxycinnamate leads to further rapid degradation of UV-A dibenzoylmethane sunscreens in the presence of ultraviolet radiation. The presence of a rosmarinic acid ester compound was found to be very effective in stabilizing the composition even in the presence of a UV-B sunscreen.

[0055] Useful inorganic sun-blocks are also preferably used in the present invention. These include, for example, zinc oxide, iron oxide, silica (such as fumed silica) and titanium dioxide.

[0056] The composition may further comprise a preservative to prevent the growth of potentially harmful microorganisms. Conventional preservatives suitable for the composition of the present invention are alkyl esters of p-hydroxybenzoic acid. Other preservatives that have recently begun to be used include hydantoin derivatives, propionates. Particularly preferred preservatives are phenoxyethanol, methylparaben, propylparaben, imidazolidinyl urea, sodium dehydroacetate, benzyl alcohol, alkanediols, most preferably 1,2-octanediol and phenoxyethanol. Preservatives should be selected in consideration of the purpose of the composition and possible incompatibility between the preservative and other ingredients. Preservatives are preferably used in an amount of 0.01% to 2% by weight of the composition.

[0057] Various other optional materials may be formulated into the composition. These may include: antimicrobial agents such as 2-hydroxy-4,2',4'-trichlorodiphenyl ether (triclosan), 2,6-dimethyl-4-hydroxychlorobenzene, and 3,4,4'-trichlorocarbonate anilide; scrubs and exfoliating particles such as polyethylene and silica or alumina; cooling agents such as menthol; skin soothing agents such as aloe vera; and coloring agents.

[0058] In addition, the composition may further comprise 0 to 10% by weight of an opacifier and a pearlescent agent, such as ethylene glycol distearate, titanium dioxide or 621 (styrene / acrylate copolymer); they can all be used to enhance the appearance or properties of the product.

[0059] Diluents other than water that can be used in the composition may include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of carriers, which can be used alone or as a mixture of one or more carriers, are as follows:

[0060] Preferably, the composition comprises an emollient. Examples of emollients that may be present include stearyl alcohol, glyceryl monoricinoleate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecane-2-ol, isocetyl alcohol, eicosanol, behenyl alcohol, cetyl palmitate, silicone oil (such as dimethicone), di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate. Esters, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cottonseed oil, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, sesame seed oil, coconut oil, peanut oil, castor oil, acetylated lanolin alcohol, petrolatum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate.

[0061] Preferably, the composition comprises a solvent such as ethanol, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, and mixtures thereof.

[0062] Advantageously, the composition may preferably comprise ingredients such as bactericides, vitamins, anti-acne actives; anti-wrinkle, anti-skin atrophy and skin repair actives, skin barrier repair actives, non-steroidal cosmetic soothing actives, artificial tanning agents and accelerators, sebum stimulants, sebum inhibitors, antioxidants, protease inhibitors, skin tightening agents, anti-itching ingredients, hair growth inhibitors, 5-alpha reductase inhibitors, ecdysin enhancers, anti-glycation agents, and mixtures thereof.

[0063] The composition may preferably comprise a powder such as, for example, chalk, talc, Fuller's earth, kaolin, starch, gums, colloidal silica, sodium polyacrylate, tetraalkyl and / or trialkylaryl ammonium montmorillonites, chemically modified magnesium aluminum silicates, organically modified montmorillonite clays, hydrated aluminum silicates, fumed silica, carboxyvinyl polymers, sodium carboxymethylcellulose, ethylene glycol monostearate, and mixtures thereof.

[0064] The compositions of the present invention may include a wide range of other optional components. The CTFA Personal Care Ingredient Handbook (2nd Edition, 1992), the entire contents of which are incorporated herein by reference, describes a wide variety of non-restrictive personal care and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples include: antioxidants, adhesives, biological additives, buffers, colorants, thickeners, polymers, astringents, fragrances, humectants, sunscreens, conditioners, pH adjusters, natural extracts, skin sensates, skin soothing agents, and skin healing agents.

[0065] The composition may also include one or more of the following ingredients: for example, chloroxylenol, zinc pyrithione (ZPT), creatine, and creatinine.

[0066] The composition is preferably in the form of a rinse-off or leave-on composition, preferably a leave-on composition.

[0067] Rinse-off compositions preferably refer to compositions which are intended / need to be removed from the body by washing with a solvent, preferably water, after application of the composition, such as, for example, hand washing compositions and face washing compositions.

[0068] A leave-on composition preferably refers to a composition which does not need to be removed from the human body after application of the composition such as, for example, skin creams, lotions, handsanitizers and deodorants.

[0069] When the composition is in the form of a leave-on composition, the composition may be in the form of a deodorant, a hand sanitizer, a lotion, a cream and a body spray.

[0070] The compositions of the present invention may preferably comprise a conventional deodorant base as a cosmetically acceptable carrier. Deodorant refers to products in stick, roll-on or propellant medium that may be used for personal deodorant benefits (e.g., application to the underarm area), which may or may not contain an antiperspirant active.

[0071] Deodorant compositions can generally be in the form of hard solids, soft solids, gels, creams and liquids, and are dispensed using an applicator suitable for the physical properties of the composition. Deodorant compositions delivered by rolling on generally include a liquid carrier. Such a liquid carrier can be hydrophobic or contain a mixture of both hydrophilic and hydrophobic liquids. They can be in the form of an emulsion or a microemulsion. The liquid carrier or carrier mixture generally constitutes 30 to 95% by weight of the composition, and in many cases 40 to 80% by weight. The hydrophobic liquid carrier generally may include one or more materials selected from the following chemical classes: silicones, hydrocarbons, branched aliphatic alcohols, esters and ethers having a melting point not exceeding 25°C and a boiling point of at least 100°C. The hydrophilic carrier liquids that can be used in the compositions herein generally include water and / or monohydric or polyhydric alcohols or water-miscible homologues. Polyhydric alcohols generally include ethylene glycol or propylene glycol, or homologues such as diethylene glycol may be used. In addition, other carriers and components suitable for deodorant compositions may be added.

[0072] In a second aspect, the present invention also provides a method for cleaning or disinfecting a surface, which comprises, in the case of a leave-on composition, a step of applying the composition of the first aspect to the surface. If the composition is in the form of a rinse-off composition, the method optionally comprises an additional step of at least partially removing the composition from the surface. Preferably, the step of at least partially removing the composition is performed within less than 5 minutes after the step of applying the composition to the surface. Preferably, the method is non-therapeutic.

[0073] In a third aspect, the present invention also provides the use of the composition as in the first aspect for antimicrobial benefit. Antimicrobial benefit preferably means that after application of the composition, residual microorganisms on the surface are significantly less. The composition of the present invention provides improved antimicrobial benefit. In particular, it provides a synergistic antiviral benefit.

[0074] In a fourth aspect, the present invention also provides use of the composition for improved hand hygiene.

[0075] The invention will now be demonstrated by the following non-limiting examples.

[0076] Example

[0077] In vitro experiments demonstrating the antimicrobial efficacy of the compositions according to the present invention evaluated using log reduction of adenovirus Test: Material:

[0078] Human adenovirus 5; strain - adenovirus 75 (ATCC-VR-5),

[0079] Feline calicivirus (FCV; strain F-9 from ATCC),

[0080] Crandell Rees cat kidney cells (CRFK; CCL-94, from ATCC),

[0081] HeLa cells (CCL-23, from ATCC),

[0082] Honokiol (98% purity, from World Way Biotech, China),

[0083] Magnolia officinalis (98% purity, from World Way Biotech, China),

[0084] 2,2'-Bisphenol (Aldrich cat. No. 115819),

[0085] Sephacryl ColumnMicroSpin TM S-400(GE Healthcare Cat#27-5140-01),

[0086] Dulbecco's modified Eagle's medium (DMEM; Sigma cat. No. D6046),

[0087] Fetal calf serum (FCS; Gibco cat. No. 16000-044),

[0088] Virus growth medium (VGM, DMEM + 2% FCS),

[0089] Ethylenediaminetetraacetic acid (EDTA; Sigma cat. No. E6758); and

[0090] 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Sigma cat. No. H3375)

[0091] The experiment was performed using the following protocol:

[0092] Antiviral effectiveness was tested according to the ASTM International test method known as E1052-11 "Standard Test Method for Evaluating the Activity of Microbicides in Suspensions Against Viruses".

[0093] 1 mL of the composition listed in Table 1 was aliquoted into sterile microcentrifuge tubes. To all of these tubes, 50 μL of adenovirus high titer virus stock was added, mixed, and kept at 24°C for 15 seconds. Thereafter, 300 μL of this mixture was added to 300 μL of neutralizer (DMEM+10%FCS+5%HEPES+1mM EDTA) and vortexed. 100 μL of each neutralization mixture was added to the sephacryl column and centrifuged at 735g for 2 minutes at 4°C. The eluate containing the virus was serially diluted in VGM and added to HeLa in the case of adenovirus. Monolayer HeLa cells were grown in 96-well cell culture plates at 37°C, 5% CO2.

[0094] Table 1:

[0095]

[0096] # The disinfectant matrix contains 62% ethanol, 3% isopropyl alcohol, up to 0.5% of minor ingredients such as polymers and fragrances, and up to 100% water.

[0097] 100 μL of each dilution prepared as described above was added to five replicate wells of a 96-well plate containing HeLa cells. In addition, each plate had cells and VGM serving as a cell control. All plates were cultured at 37°C, 5% CO2, and observed daily for virus-specific cytopathic effects for a period of up to 5 days. At the end of the culture period (5 days), the cells were analyzed using a 4% dextrose ion exchange assay as described in annexure C of BS EN 14476:2013. The TCID50 (tissue culture infectious dose, virus titer) was calculated by the formula. The results are tabulated in Table 2 below as Log reduction of virus counts.

[0098] Table 2

[0099]

[0100]

[0101] The data for Example A in Table 2 above show that the adenovirus titer in the case of the control was 5.5 ± 0.24. This was the virus titer obtained after treatment with water alone (Example A; control). The log reduction in adenovirus titer for all other examples (Examples B, C and 1 to 5) was calculated by subtracting the TCID50 values ​​of these examples from the TCID50 of Example A.

[0102] The data in Table 2 above show that the Examples within the scope of the present invention (Examples 1 to 5) provide much higher log reductions when compared to the Examples outside the scope of the present invention (Examples A to C).

[0103] The data further show that a 0.4 log reduction in adenovirus titer was obtained due to treatment with the disinfectant matrix alone (Example C). However, when treated with the composition according to the invention (Examples 1 to 7), an almost 1 log reduction in adenovirus (non-enveloped virus) titer was obtained. A 1 log reduction in virus counts of a non-enveloped virus is considered very effective.

[0104] In vitro experiments demonstrating the antimicrobial benefit of the composition according to the invention evaluated using log reduction in FCV:

[0105] The protocol for this experiment was the same as disclosed in the adenovirus section above. However, in the case of FCV, CRFK cells were used instead of HeLa and the culture time was 2 days instead of 5 days.

[0106] The treatments listed in Table 3 below were evaluated for antimicrobial benefit using the protocol described previously.

[0107] Table 3

[0108]

[0109]

[0110] The resulting log reductions in FCV titers are tabulated in Table 4 below.

[0111] Table 4

[0112]

[0113] The TCID50 of Example D (control) was found to be 5.6 ± 0.2. This was the viral titer found after treatment with water alone (i.e., control). The log reduction in titer of FCV for Examples E, F, 6, and 7 was calculated by subtracting the TCID50 of these Examples from the TCID50 of Example D. The data in Table 4 show that the composition according to the present invention comprising alcohol and honokiol (Example 6) showed a log reduction of almost 1 in FCV (non-enveloped virus). It was found that when honokiol was used in addition to honokiol and alcohol (as shown in Example 7), the antimicrobial benefit was further enhanced.

[0114] Another method of demonstrating the antimicrobial efficacy of compositions outside the scope of the present invention evaluated using log reduction of adenovirus In vitro experiments:

[0115] The protocol for this experiment was the same as disclosed in the adenovirus section above.

[0116] Table 5

[0117] Example water Disinfectant Matrix Honokiol Magnolia G 100 - - - H 27 72.5 0.25 0.25

[0118] Note: The ethanol content in the composition of Example H is 45%, and the isopropanol content is 2.1%.

[0119] Table 6

[0120]

[0121] The TCID50 of Example G was found to be 5.9. This was the viral titer found after treatment with water alone (ie, the control). The log reduction in titer of the adenovirus of Example H was calculated by subtracting the TCID50 of Example H from the TCID50 of Example D.

[0122] The data in Table 6 show that when ethanol was combined with bisphenols (i.e., honokiol and magnolol) in amounts not in accordance with the present invention, as shown in Example H, a log reduction in adenovirus titer as low as 0.6 was found, which is less than a 1 log reduction, i.e., no synergistic antiviral benefit was obtained.

[0123] It is concluded that compositions comprising certain amounts of at least one bisphenol and at least one monohydric non-phenolic alcohol provide synergistic antimicrobial benefits, and in particular, provide synergistic antiviral benefits.

Claims

1. An anti-adenovirus composition comprising: a. 0.1 to 10 wt % of at least one bisphenol, wherein the bisphenol is magnolol and / or honokiol; and b. 60 to 80 weight percent of a monohydric non-phenolic alcohol, wherein the alcohol is selected from ethanol, isopropanol, and mixtures thereof.

2. The composition of claim 1, wherein the selected bisphenol is honokiol.

3. The composition of any one of claims 1 to 2, further comprising 1 to 80 wt% of a surfactant.

4. The composition of any one of claims 1 to 2, further comprising a cosmetically acceptable base.

5. The composition of any one of claims 1 to 2, wherein the composition is in the form of a rinse-off composition.

6. The composition of any one of claims 1 to 2, wherein the composition is in the form of a leave-on composition.

7. A non-therapeutic method of cleaning or disinfecting a surface comprising the step of applying to the surface a composition as claimed in any one of claims 1 to 6.

8. The non-therapeutic method of claim 7, wherein the composition is in the form of a rinse-off composition and wherein there is an additional step of at least partially removing the applied composition.

9. The non-therapeutic method of claim 8, wherein the step of at least partially removing the composition is performed within less than 5 minutes after the step of applying the composition to the surface.

10. Non-therapeutic use of a composition as claimed in any one of claims 1 to 6 for antimicrobial benefit.

11. Non-therapeutic use of a composition as claimed in any one of claims 1 to 6 for improved hand hygiene.

Images